A novel pharmacological entity toward integrated multimodal immunotherapy
- PMID: 39721827
- DOI: 10.1016/j.tips.2024.12.001
A novel pharmacological entity toward integrated multimodal immunotherapy
Abstract
Most solid tumors are insensitive to single-agent immunotherapy, calling for the development of combinatorial treatment regimens. Recently, Lin and collaborators developed a pharmacological platform enabling the combination of different immunotherapies into a single chemical entity. This approach may effectively circumvent obstacles associated with the simultaneous delivery of multiple immunotherapeutic agents.
Keywords: CD8(+) cytotoxic T lymphocyte; dendritic cell; immune checkpoint inhibitor; immunoevasion; multimodal targeting chimera; triple orthogonal linker.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests L.G. is/has been holding research contracts with Lytix Biopharma, Promontory, and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, AbbVie, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. The other authors have no conflicts of interest to declare.
Comment on
-
Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment.Cell. 2024 Dec 26;187(26):7470-7491.e32. doi: 10.1016/j.cell.2024.10.016. Epub 2024 Nov 5. Cell. 2024. PMID: 39504957
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
